;Geopolitical and Regulatory ChangesMost Favored Nation drug pricing models make global waves in 2026Read moreImplications of the Most Favored Nation policy for the EU pharmaceuticals marketRead moreTariff enforcement meets the FCA: Liability under the Trump Administration’s tariff regimeRead moreIncreased use of CMMI authority to change U.S. Medicare payment policyRead moreNet price and confidentiality: A key challenge in the pharmaceutical industryRead moreFrench pharmaceutical market access amid budgetary strain and cost containmentRead moreFDA targets direct to consumer prescription drug advertisingRead moreDTC balancing act set to continue for pharmaceutical industry in 2026Read moreEU liability landscape shifts as AI-enabled devices face diverging MDR, PLD rulesRead moreBIOSECURE Act enacted to restrict U.S. transactions with "companies of concern"Read moreU.S. Country of Origin compliance: Navigating an evolving enforcement landscapeRead moreRenewed focus on Bayh-Dole and federally funded inventionsRead moreThe hospital as a global institutionRead morePrevious pageNext page
